ucsf logo

Margaret C. Fang, MD, MPH

Internal Medicine • Hospital MedicineMedical Director, Anticoagulation Clinic
Portrait of Margaret C. Fang
Portrait of Margaret C. Fang
ucsf logo

Margaret C. Fang, MD, MPH

Internal Medicine • Hospital MedicineMedical Director, Anticoagulation Clinic

On this page

About me

Dr. Margaret Fang is a hospital-based physician and researcher who serves as medical director of the UCSF Anticoagulation Clinic. As a hospitalist, she provides care for inpatients at UCSF Medical Center and also supervises resident physicians and medical students.

With a broad interest in cardiovascular epidemiology, Fang specifically studies the use of anticoagulants in patient care. She also contributes to ongoing collaborative research projects, including the AnTicoagulation and Risk Factors In Atrial Fibrillation (ATRIA) study and the Cardiovascular Research Network's venous thromboembolism study.

Fang earned her medical degree from Northwestern University Feinberg School of Medicine. She completed a residency in internal medicine at Beth Israel Deaconess Medical Center and a fellowship in general internal medicine at Massachusetts General Hospital. She also earned a master of public health degree from the Harvard T.H. Chan School of Public Health. She joined UCSF in 2003.

Education & training

Board certification

  • Internal Medicine, American Board of Internal Medicine

Residency

  • Internal Medicine, Beth Israel Deaconess Medical Center - East Campus

Internship

  • Internal Medicine, Beth Israel Deaconess Medical Center - East Campus

Degree

  • MD, Northwestern University

My expertise

Please check with your health insurance plan regarding coverage for this type of care. Not all providers at UCSF Health are covered by every insurance plan.

For informational purposes only, a link to the federal Centers for Medicare and Medicaid Services (CMS) Open Payments web page is provided here. The federal Physician Payments Sunshine Act requires that detailed information about payment and other payments of value worth over ten dollars ($10) from manufacturers of drugs, medical devices, and biologics to physicians and teaching hospitals be made available to the public.